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SINTESIS, PENCIRIAN DAN PENILAIAN BIOLOGI 
KALKON BERASASKAN NAFTALENA DAN KUMARIN 
ABSTRAK 
Kajian ini dimulakan dengan sintesis dan pencirian dua siri utama 
bahan pemula: pengalkilan naftaldehid (2-8) dan pengasetilan kumarin tertukar 
ganti (9-11). Bahan pemula yang diperoleh dikenalpasti melalui kaedah 
spektroskopi seperti inframerah transformasi Fourier (FTIR), resonans magnet 
nukleus (NMR) dan mikroanalisis CHN. Analisa pembelauan sinar-X hablur 
tunggal (XRD) juga dijalankan dengan hablur bagi sebatian 3, 34, dan 41 
menghablur dalam sistem kristal triklinik. Lima siri kalkon kemudiannya 
disintesis melalui kaedah kondensasi Claisen-Schmidt dengan tiga siri 
diterbitkan daripada kumarin asetil tertukar ganti (12-33) dan dua siri yang lain 
diterbitkan daripada asetofenon tertukar ganti (34-46). Semua kalkon yang 
disintesis telah dicirikan dengan analisa unsur (CHN), spektroskopi FTIR , 1H-
NMR, 13C-NMR, DEPT 135, 1H-1H COSY, 1H-13C HMQC dan 1H-13C 
HMBC. Kalkon 23, 28, 34, dan 41 telah dipilih untuk analisis kristolografi. 
Kalkon yang disintesis telah dinilai bagi ciri farmakologi (anti-kanser) terhadap 
sel kanser payudara (4T1) dan sel fibroblas (NIH - 3T3) dengan cisplatin 
sebagai kawalan positif. Berdasarkan data yang diperoleh, kalkon yang 
mengandungi gelang kumarin menunjukkan kesitotoksi yang lebih kuat 
terhadap sel kanser payudara berbanding dengan kaklon yang mengandungi 
gelang fenil biasa. Sebatian 17 menunjukkan aktiviti perencatan tertinggi 
xxiii 
 
terhadap titisan sel kanser 4T1 di kalangan kalkon yang disintesis dan lima kali 
ganda (IC50 = 3 ± 0.00) lebih aktif berbanding dengan cisplatin (IC50 = 16.5 ± 
0.71). Kalkon 13, 14, 15, 16, 24 dan 31 juga menunjukkan aktiviti perencatan 
tinggi terhadap titisan sel kanser 4T1 dengan IC50 < 20.5 μM. Keputusan juga 
menunjukkan bahawa kalkon terfluorin (nilai IC50 antara 28-62 μM) mungkin 
menjadi ejen anti-kanser payudara yang lebih baik berbanding dengan kalkon 
tanpa fluorin (IC50 > 92.5 μM). 
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SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL 
EVALUATION OF NAPHTHALENE- AND COUMARIN-
BASED CHALCONES 
ABSTRACT 
This study was started by the synthesis and characterization of two 
main series of starting materials: alkylation of naphthaldehydes (2-8) and 
acetylation of substituted coumarins (9-11). The starting materials thus 
obtained were elucidated by the spectroscopic methods such as fourier 
transform infrared (FTIR), nuclear magnetic resonance (NMR) and CHN 
microanalyses. Single crystal X-ray diffraction (XRD) analyses have also been 
carried out wherein the crystals of compound 3, 34 and 41 crystallized in a 
triclinic crystal system. Five novel series of chalcones were subsequently 
synthesized by means of Claisen-Schmidt condensation wherein three series 
were derived from substituted acetyl coumarins (12-33) and the remaining two 
series was derived from substituted acetophenones (34-46). All the synthesized 
chalcones were characterized by elemental analysis (CHN), FTIR, 1H-NMR, 
13C-NMR, DEPT 135, 1H-1H COSY, 1H-13C HMQC and 1H-13C HMBC 
spectroscopy. Selected chalcones, 23, 28, 34, and 41 were selected for 
crystallography analysis. The synthesized chalcones were evaluated for their 
pharmacological (anti-cancer) properties against breast cancer cell (4T1) and 
fibroblast cell (NIH-3T3) with cisplatin as positive control. Based on the data 
obtained, chalcones comprised of coumarin rings showed more potent 
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cytotoxicity against breast cancer cell compared to chalcones comprised of 
common phenyl rings. Compound 17 exhibited the highest inhibitory activity 
against 4T1 cancer cell line among the synthesized chalcones and five times 
(IC50 = 3±0.00) more active compared to cisplatin (IC50 = 16.5±0.71). 
Chalcones 13, 14, 15, 16, 24 and 31 also showed high inhibitory activities 
against 4T1 cancer cell line with IC50 < 20.5 µM. The results also indicated 
that fluorinated chalcones (IC50 value ranged from 28-62 µM) may serve as 
better anti-breast cancer agents than the chalcones without fluorine (IC50 > 92.5 
µM). 
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CHAPTER 1: INTRODUCTION 
1.1 Chalcone  
 Chalcones, a class of naturally occurring pigments which also known as 
benzelideneacetophenones are aromatic ketones that form the central core for a variety 
of important biological compounds (Rachmale et al., 2011). They are abundant in 
edible plants and are considered to be precursors for flavonoids biosynthesis in plants. 
Chalcones can also be synthesized in laboratory (Patil et al., 2009). Flavanoids consist 
mostly of antocynin, flavones and flanols, while chalcone, dihydroxychalcone and 
aurone are known as minor classes of flavanoids (Harborne, 1967). 
Chemically, chalcones are open chain flavonoids in which the two aromatic 
rings are joined together by three carbons from the α,β-unsaturated carbonyl system 
(enone), which is a typical 1,4-conjugate addition (Michael addition) acceptor (Ko et 
al., 2003). The general chemical structure of a chalcone is depicted in Figure 1.1. 
O
 
Figure 1.1: General structure of chalcone. 
The term ‘chalcone’ also refers to the structurally simple and important plant 
secondary metabolite, which serves as defense mechanism in plants to counteract 
reactive oxygen species (ROS) to prevent damage by micro-organisms, insects or 
herbivores (Vaya et al. 1997). Chalcone strongly inhibits the polymerization of tubulin 
by binding to the colchicines-binding site (Lawrence et al., 2006). 
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A universal numbering system has been applied to distinguish the two aromatic 
rings of chalcones in which the two rings are labeled as A and B respectively. Figure 
1.2 shows the chemical structure of 1-(4-hydroxyphenyl)-3-(2’,4’-dihydroxyphenyl)-2-
propen-1-one, with the corresponding atomic numbering (Bohm, 1998). 
O
HO OH OH
1
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Figure 1.2: Chemical structure of 1-(4-hydroxyphenyl)-3-(2’,4’-dihydroxyphenyl)-2- 
                   propen-1-one labeled with universal numbering system. 
Chalcone is also acted as an important intermediate in biosynthesis of other 
classes of flavonoids in natural plants. Figure 1.3 shows chalcone acts as a main center 
core structure that undergoes different biosynthetic pathways to produce various classes 
of flavonoids such as flavanone (I), flavon (II), auron (III), flavonol (IV), antocianidin 
(V), dihydroflavonol (VI), dihydrochalcone (VII) and isoflavone (VIII) (Wong, 1976). 
The conversion of chalcone to other classes of flavonoids is catalyzed by certain plant 
enzymes. For an example, the metabolic pathway continues through a series of 
enzymatic modifications to yield I from chalcones, where research showed chalcone-
flavanone isomerase was the enzyme that enhanced the biosynthesis (Swain, 1976). 
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Figure 1.3: Chalcone as an intermediate in biosynthetic pathways leading to different 
classes of flavonoids.  
 
In the recent years, synthesis of chalcones and their derivatives have attracted 
considerable attention due to their significant biological activities, sufficient 
fluorescence in the visible light range, large Stokes shifts and high quantum yields 
(Zhang et al., 2010). Chalcones have been reported to display an impressive array of 
biological activities such as antioxidant, antibacterial, anthelmintic, amoebicidal, 
antiulcer, antiviral, insecticidal, antiprotozoal, antileishmanial, antimalarial, antifungal, 
anti-inflammatory, anticancer, cytotoxic and immunosuppressive (Nowakowska, 2006; 
Trivedi et al., 2008; Srinivasan et al., 2009). 
 
I 
V 
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1.2  Problem Statement 
There were several basic catalysts that have been applied in the synthesis of 
chalcone, such as sodium hydroxide, sodium methoxide, barium hydroxide, 
hydroapatite and lithium hydroxide. Even though these reactions provide advantages 
due to their Heterogenous nature. However, most of them require rather complicated 
neutralization process to obtain the synthesized compound. Recently, to improve the 
production-in synthesis of chalcones, piperidine has been tried. In this study, piperidine 
mediated chalcones formation without the neutralization requirement to obtain the solid 
yield. Hence, it is among the suitable candidate to be used as support in chalcone 
synthesis in respect to its unique properties.  
1.3       Objectives of the research 
In view of the important and uses of chalcones and their derivatives, this 
research project is aims to undertake an in-depth study on a few series of new 
chalcones. 
The objectives of this project are: 
1. To synthesize novel chalcones from inexpensive commercially available aromatic 
compounds. 
2. To synthesize novel coumarin- and naphthalene-based chalcone derivatives with 
different alkyl chain length. 
3. To elucidate all intermediary and targeted compounds using spectroscopic 
techniques (FT-IR, 1D-NMR, 2D-NMR), CHN elemental analysis and X-ray 
crystallography. 
4. To evaluate the anti-cancer activity of the synthesized chalcones. 
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1.4 Scope of Study 
The scope of this study is basically to synthesize and characterize the chalcones using 
Claisen-Schmidt condensation method and to determine the anti-cancer activity for the 
chalcone syntehsized. There are some significant tasks to be carried out in order to 
achieve the objective of this study. 
I. In this study, the individual starting material, coumarin and naphthalene will react to 
synthesized chalcones. 
II. The characterization of the result chalcones using fourier transform infrared (FTIR), 
nuclear magnetic resonance (NMR), CHN microanalyses and single crystal X-ray 
diffraction (XRD).  
III. Pharmacological (anti-cancer) properties of the synthesized chalcones will be 
evaluated through inhibition rate against breast cancer cell (4T1) and fibroblast cell 
(NIH-3T3) with cisplatin as positive control. 
IV. Analyst the relationship of the alkyl group carbon chain lengths with the 
synthesized chalcones biological activity.  
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CHAPTER 2: LITERATURE REVIEW 
2.1       Starting materials 
For this research project, two naturally abundant compounds had been chosen as 
starting materials: coumarin and naphthalene. Both are valuable starting materials that 
represent a vast family of compounds which were naturally found in plants and are 
interesting bioactive targets for many organic medicinal chemists. 
2.1.1     Coumarin  
Coumarin; also known as 2H-1-benzopyran-2-one, is a fragrant organic 
chemical compound and naturally occurring polyphenolics distributed widely in plants 
and microorganisms. Vogel (1920) had isolated the first coumarin (Figure 2.1) from the 
fruit of Dipteryx odorata Wild. Coumarin can occur in two basic forms, either attached 
to sugar glucose or as a free molecule.  
O O 
Figure 2.1. Structure of a coumarin. 
Due to large number of natural products contain coumarin heterocyclic as 
nucleus, coumarins occupy an important position in natural and synthetic organic 
chemistry. They are widely used as additives in food, perfumes, photochemotherapeutic 
agents, insecticides and in optical brighteners (Fulchand et al., 2008). In particular, 
coumarin derivatives have been found to exhibit a variety of biological activities such 
as antitumor (Santana et al., 2000), antioxidant (Guiotto et al., 1995), anti-inflammatory 
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(Ploypradith et al., 2004), anticoagulant (Borges et al., 2005), antibacterial (Maria et al., 
2013), anti-cancer (Riveiro et al., 2008; Belluti et al., 2010), anti-HIV (Zhao et al., 
1997; Mahajan et al., 2009), and antiproliferative (Jung et al., 2009) properties. Among 
these properties, cytotoxic effects were most extensively examined. Neo-tanshinlactone 
(Figure 2.2), a coumarin containing compound, has shown significant inhibition activity 
against two ER+ human breast cancer cell lines, which has been associated with low 
toxicity and has raised considerable interest because of its potential beneficial effects on 
human health. Nevertheless, others coumarin-derivatives such as Geiparvarin, 
Umbeliferone, Xanthyletin and Seselin (Figure 2.2) have provoked great interest for 
their possible therapeutic uses (Sashidhara et al., 2010). 
O
O
O
O OHO
Neo-Tanshinlactone
Umbeliferone
O
O O
O
O
Geiparvarin
O O O
Seselin
O O O
Xanthyletin
 
Figure 2.2. Chemical structures of some naturally occurring coumarins with potent 
anticancer activity. 
Over the years, scientists had developed many strategic pathways for the 
synthesis of coumarins in laboratory. These include use of the Reformatsky, Wittig, 
Pechmann, Perkin, Claisen and Knoevenagel reactions. Knoevenagel reaction has been 
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applied in this project. The Knoevenagel reaction involves the condensation of 
benzaldehydes with activated methylene compounds and amine as a catalyst in organic 
solvents. Knoevenagel reaction method was more preferable compared to other methods 
because of its less severe reaction conditions (Knoevenagel et al., 1984).   
2.1.2 Naphthalene 
 Naphthalene is the simplest member of polycyclic aromatic hydrocarbons which 
consists of two fused benzene rings (Price & Jayjock, 2008). Naphthalene (Figure 2.3) 
appears as white crystalline solid with a characteristic odor and readily sublimes at 
room temperature. This compound is easily generated during burning of wood or 
cigarette, grilling of meats, petroleum refining and distillation of coal tar (ADSTR, 
2005). 
 
Figure 2.3. Structure of naphthalene. 
Naphthalene has been largely used in manufacture as a chemical intermediate 
including moth repellents, plastics, wetting agent, lavatory scent discs, surfactant, dyes, 
resins, and soil fumigants (Brusick, 2008). Recent studies showed that naphthalene 
derivatives have attracted a great interest not only for their significant biological and 
photophysical properties (thermo- and photochromism, and non-linear optical 
behavior), but also as model compounds for assessing the nature of the hydrogen 
bonding (Martinez et al., 2011).  
Naphthalene and its derivatives have been reported to possess a wide spectrum 
of biological activity such as anti-inflammatory (Huang et al., 2003; Jing et al., 2013), 
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anti-cancer (Andrea et al., 2012), anti-mycobacterial (Ram et al., 2010; Upadhayaya et 
al., 2010), anti-tubulin (Alvarez et al., 2007), antimicrobial (Yapici et al., 2005), anti-
proliferative (Sheila et al., 2013), anti-protozoal (Donald et al., 2009), and bactericidal 
activity (Misra & Kushwaha, 1977). Study conducted by Tanaka et al. (2009) shows 
that anti-inflammatory potency of naphthalene-chalcone hybrid has been associated 
with the increase in HO-1 expression (Tanaka et al., 2009). Additional to that, 
naphthalene has been shown as an ideal component of a fluorescent chemosensor due to 
its short fluorescence lifetime, low fluorescence quantum yield and ability to act as a 
donor as well as an acceptor (Sahana et al., 2011).  
Zhou and his co-workers (2009) had extracted a naphthaldehyde derivative 
characterized as 6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-7-metho 
xy-3,4-dihydro-2-naphthaldehyde (Figure 2.4) from seeds of Vitex negundo, which 
proven to possess cytotoxic effect on breast, prostate, and ovarian cancer cells and 
induces apoptosis with cleavage in poly ADP ribose polymerase protein, up-regulation 
of Bax, and down-regulation of Bcl-2. Furthermore, Maioral et al. (2012) shown that 
synthetic chalcones, derived from 1-naphthaldehyde and 2-naphthaldehyde, possessed 
cytotoxic effect on human acute myeloid leukemia K562 cells and on human acute 
lymphoblastic leukemia Jurkat cells. From the experiment done by David (2004) also 
revealed that 2-hydroxy-1-naphthaldehyde derivatives showed higher activity and 
selectivity toward a range of neoplastic cells relative to normal cells. 
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Figure 2.4. Chemical structure of 6-hydroxy-4-(4-hydroxy-3-methoxyphenyl)-3-
hydroxymethyl-7-methoxy-3,4-dihydro-2-naphthaldehyde extracted from seeds of Vitex 
Negundo. 
2.2 Methods to synthesize chalcone 
A chalcone can be prepared by Claisen-Schmidt condensation between a 
benzaldehyde and an acetophenone in the presence of base catalyst followed by 
dehydration to yield the corresponding product. It is also possible to synthesize 
chalcone under acidic conditions using perchloric acid and acetic acid (Siddiqui et al., 
2008). Several other methods have been developed as well to synthesize chalcone, such 
as Heck reaction (Bianco et al., 2004), Hiyama coupling (Hatanaka & Hiyama, 1988), 
Negishi coupling (King et al., 1977), Stille reaction (Santos et al., 2007), Suzuki 
reaction (Suzuki, 1998) and so on. 
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2.2.1 Claisen-Schmidt reaction 
 Claisen-Schmidt reaction also known as aldol condensation has been the most 
convenient and widely used method for obtaining chalcones. It has been the most 
important enolate reactions of carbonyl compounds in which the acetophenone was 
reacted with benzaldehyde in the presence of alkali or acid as catalyst to form new 
carbon-carbon bonds. Condensation combined these two carbonyl compounds, often 
with the loss of small molecule such as water or an alcohol (Wade, 2006).  
 The condensation of the Claisen-Schmidt reaction can be carried out by using 
various basic catalysts such as sodium hydroxide (Alston & Albert, 2004), potassium 
hydroxide, sodium methoxide (Rojas et al., 2002), barium hydroxide (Krohn et al., 
2002), hydroapatite and lithium hydroxide (Zahouily et al., 2003). It is also possible to 
synthesize chalcone under acidic condition by using silica-sulphuric acid (Zhang et al., 
2003), dry hydrochloric acid, perchloric acid and acetic acid (Siddiqui et al., 2008). 
 Solhy and his co-workers found out that hydroxyapatite was a very efficient 
heterogeneous catalyst for the preparation of chalcone derivatives via Claisen–Schmidt 
condensation using microwave irradiation (Figure 2.5). The catalyst was easily 
recovered and efficiently re-used. Solhy had combined hydroxyapatite with water (act 
as co-catalyst) to produce various substituted chalcones with excellent yield of 95% 
(Solhy et al., 2010). 
O O
+
Hydroxyapotite (HAP)
H2O, MW (700watt)
O
R1 R1  
 
Figure 2.5: Synthesis of various substituted chalcones in the presence of water and 
                   hydroxyapatite as catalyst via Claisen–Schmidt condensation using  
                   microwave irradiation. 
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The mechanism of the Claisen-Schmidt reaction was proposed by Nayak and 
Rout in 1970. Gasull et al. (2000) has re-analyzed the mechanism of Nayak and 
proposed a new mechanism that has been used in most of the modern organic textbooks. 
As illustrated in Figure 2.6, there are several steps involved in the formation of 
chalcone:  
Step 1: A base removes an α proton to form an enolate ion. 
Step 2: Nucleophilic addition of the enolate ion to a carbonyl group. 
Step 3: A configurational equilibrium between cis-s-cis and trans-s-trans isomers. 
Step 4: Protonation of alkoxide by water molecule to form a neutral intermediate. 
Step 5: Intramolecular dehydration of the neutral intermediate to give the chalcone. 
O
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
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O OH
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Step 2
Step 1
Chalcone
Intermediate
Trans-isomer Cis-isomer
Enolate Ion
 
 
Figure 2.6: Proposed reaction mechanism for the chalcone formation under alkaline  
                   condensation in 65% EtOH-H2O by Gasull et al. (2000). 
Trans-isomer 
Cis-isomer 
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2.2.2 Suzuki reaction 
 The Suzuki coupling reaction is the palladium-catalyzed cross coupling 
between organoboronic acid and aryl halides. Recent developments have extended 
the application of Suzuki reaction where the starting materials are not restricted to 
aryls, but include alkyls, alkenyls and alkynyls. Several reports have described the 
synthesis of polysubstituted chalcones based on the Suzuki reaction (Figure 2.7). The 
reaction has been performed using activated form of acid such as acyl chlorides, acid 
anhydrides or thio-esters coupling with phenylboronic acid (Eddarir et al., 2003).  
R2
R1
B
OH
OH
Cl
O
+
O
(PPh3)4Pd(0)
Cs2CO3, Toluene
R1
R2
 
Figure 2.7. Synthesis of chalcones by Suzuki coupling between cinnamonyl chloride 
and  
                   phenylboronic acid.  
 
The advantages of this reaction are the substituents on the acryl chloride or on 
the boronic acid did not affect the reaction mechanism, the selection of coupling site 
was quit specified and unaffected by the presence of water. Other than that, the 
Suzuki coupling is applicable in laboratories as well as in industrial processes due to 
the inorganic by-product of the reaction is non-toxic and easily removed from the 
reaction mixture (Suzuki, 1998). 
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2.2.3 Heck reaction 
 The Heck reaction (also called the Mizoroki-Heck reaction) is a palladium 
catalyzed chemical reaction involves the coupling between aryl halide and aryl 
alkene in the presence of base (Heck & Nolley, 1972). This reaction was originated 
by Tsutomu Mizoroki (1971) which described the reaction between iodobenzene and 
styrene to form stilbene with potassium acetate base and palladium chloride catalyst 
(Figure 2.8).  
I
+ + CH3COOK
PdCl2
EtOH, Reflux
+ CH3COOH + KI
 
Figure 2.8. The reaction scheme by Tsutomo Mizoroki (1971). 
 The reaction was further modified by Heck to eliminate two major difficulties 
found in Mizoroki reaction: difficulty in obtaining the required organomercury (lead 
or tin compounds) and the problem of working with thick slurries of salts, 
particularly if the reaction is carried out catalytically in palladium (Heck & Nolley, 
1972). The improved reaction differs in lack of solvent, selection of catalyst and base 
used (Figure 2.9). 
I
+
Pd(OAc)2, nBu3N
Solventless, 100oC
 
Figure 2.9. The reaction scheme by Richard F. Heck (1972). 
 Over the last few years, chalcones had been synthesized using the Heck 
coupling reaction. Palladium-catalyzed Heck coupling reaction between the aryl 
vinyl ketone with the aryl iodide will yield the corresponding chalcone (Figure 2.10) 
(Bianco et al., 2004). This procedure affords the desired chalcone in yields that are 
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always higher than those using conventional methods such as Claisen-Schmidt 
condensation. It is possible to design various novel chalcone derivatives by 
monitoring the aryl halides or aryl vinyl ketones (Bianco et al., 2003; Reichwald et 
al., 2008).  
O
OMeMeO
I
OAc
+
MeO OMe
O
OAc
 
Figure 2.10. Chalcone synthesis by Heck coupling reaction. 
 
2.3  Bioactivities of chalcones 
Cancer (also known as a malignant neoplasm) is a broad group of various 
diseases that involving uncontrolled, rapid and pathological proliferation of 
unregulated cell growth.  Being the second leading cause of death in developing as 
well as advanced countries, it had increased the pressing need for new anticancer 
agents with high potency, less toxicity in non-cancerous cells, and unique targets of 
action (Chari et al., 1992).  
Chemotherapy had been the most common treatment for diseases especially 
by killing micro-organisms such as prokaryotes, eukaryotes and cancerous cells. The 
development of novel and efficient drugs by molecular manipulation of promising 
lead compounds is still a major line of approach. Following this aim hybrid 
molecules were designed from two natural occurring compounds: naphthalene and 
coumarin. Naphthalene and coumarin derivatives have well known pharmacological 
activities such as antimicrobial (Yapici et al., 2005), anti-tubulin (Huang et al., 
2003), anti-mycobacterial (Upadhayaya et al., 2010), antitumor, anti-inflammatory, 
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anti-HIV (Nohemi et al., 2009), antithrombotic (Alvarez et al., 2007), cardio 
protectors or enzymatic inhibitors (Park & Jang, 1995).  
The hybrid molecules, chalcones, precursors of open chain flavonoids and 
isoflavonoids are present in edible plants, and have displayed a broad spectrum of 
pharmacological activity. Changes in their structure have offered a high degree of 
diversity that have proven useful for the development of new medicinal agents 
having improved potency and lesser toxicity (Rahman, 2011). The chemotherapeutic 
effects of various chalcones and their derivatives against a wide variety of 
microorganisms and diseases are given in Table 2.1. 
Table 2.1: Biological applications of chalcones and their derivatives. 
Compounds Biological 
application  
Reference 
O
OCH3
N
 
 
Inhibitors of malaria 
parasite 
(Chloroquine-sensitive 
P. falciparum) 
 
Awasthi et al.  
N(HO)2B B(OH)2
CH3
O
 
 
Anti-cancer activity 
 
 
Achanta et al. 
 
O
OH
OH
OHHO
 
 
Anti-inflammatory 
 
Yadav et al. 
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O O
OH O
CH3 
 
Anti-bacterial 
(Against Gram +ve 
bacteria, 
Staphylococcus 
aureus) 
 
Hamdi et al. 
 
O
N
OCH3
N N
 
 
Anti-filarial 
(Setaria cervi using 
GST enzyme as a drug 
target) 
 
Awasthi et al. 
 
O
Cl
OHHO
 
 
Monoamine Oxidase 
(MAOs) inhibitory 
 
Chimenti et 
al. 
 
O
CH3
H3CO3S
 
 
Cyclooxygenase 
(COX) inhibitory 
 
Zarghi et al. 
 
O
SCH3
HO
 
 
Anti-oxidant 
 
Vasil’ev et al. 
 
O
OCH3
O
 
 
Anti-convulsant 
 
Kaushik et al. 
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O
SCH3
S
 
 
Anti-fungal 
 
Bag et al. 
 
O
OCH3
N
N N
 
 
Anti-filarial 
 
Awasthi et al. 
 
   
In 2000s, a broad series of various chalcones derivatives had been 
synthesized and evaluated for their pharmacological activities. Achanta et al. (2006) 
had reported the anticancer and the mechanism of action of eight boronic chalcones 
derivatives. From the test result, boronic chalcones shown potent growth inhibition 
activity in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay and colony formation assay with IC50 values of <1.5 µM. Mechanistic studies 
showed that boronic chalcones induced significant cytotoxic effect in cancer cells by 
inhibitied the chymotrypsin like activity of the 20S proteasome in vitro.  
 Romagnoli et al. (2008) had synthesized a series of chalcone-like agents, in 
which the α,β unsaturated bond of the enone system is embedded within a thiophene 
ring were evaluated  for antiproliferative activity and inhibition of tubulin assembly 
and colchicine binding to tubulin. The replacement of the double bond with a 
thiophene maintained antiproliferative activity (IC50 < 2 µM) and electron-releasing 
group (ERG) caused only minor changes in antiproliferative activity. The 
synthesized compounds were found to inhibit the growth of several cancer cell lines 
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at nanomolar to low micromolar concentrations and some compounds (IC50, 0.8 µM) 
having twice the potency of antitubulin agent CA-4 (IC50, 1.4 µM).  
 Echeverria et al. (2009) had reported the relationships between the structural 
characteristic of synthetic chalcones and their antitumoral activity toward 
hepatocellular carcinoma cells (HepG2). From the calculated reactivity indexes and 
the adiabatic electron affinities, it shown that the absence of methoxyl substituents 
has the major structure reactivity pattern along the series. Due to this, the chalcone 1-
(2-hydroxyphenyl)-3-phenylprop-2-en-1-one was found to be possessed the most 
active structure-activity between the chalcone structure and the apoptosis in HepG2 
cells.  
 Recently, another series of chalcones were synthesized and evaluated by 
Llango et al. (2010) for their in vitro cytotoxic activity by microculture Tetrazolium 
Test Assay method using two breast cancer cell lines MCF-7 and T47D. The 
synthesized chalcones shown significant cytotoxicity against both of the cell lines 
and values lied between 52-89 µM. Due to the presence of nitro group in the 
compound, N-(4-hydroxy-3-(3-(4-nitrophenyl)acryloyl)phenyl)acetamide showed 
better activity than other compounds.  
Szliszka et al. (2010) had synthesized five chalcones that hybrided with 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Results showed 
that all the five tested chalcones markedly augmented TRAIL-mediated apoptosis 
and cytotoxicity in prostate cancer cells and confirmed the significant role of 
chalcones in chemoprevention of prostate cancer. Their study suggested that 
chalcones help anticancer immune defense in which endogenous TRAIL takes part.  
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CHAPTER 3: EXPERIMENTAL 
3.1 Chemicals 
 All the chemicals were used as received without further purification. Table 
3.1 summarizes the chemicals used in this study. 
Table 3.1: List of chemicals used in this study. 
Chemicals Source 
1-Bromoethane Merck 
1-Bromobutane Fluka 
1-Bromohexane Merck 
1-Bromooctane  Merck  
1-Bromodecane Merck 
1-Bromododecane Merck 
1-Bromotetradecane Merck 
2-Hydroxyacetophenone Merck 
2-Hydroxybenzaldehyde Merck 
2-Hydroxynaphthaldehyde Fluka 
3-Acetylcoumarin Sigma-Aldrich 
4-Fluoro-2-hydroxyacetophenone, 98% Sigma-Aldrich 
4-Hydroxycoumarin Merck 
Acetic acid (glacial) Merck 
Acetone QRec 
Deuterated chloroform, CDCl3, with TMS (0.03 vol.%), 
deuteration degree min. 99.8% 
Merck 
Diethyl ether QRec 
Dimethylformamide (DMF) QRec 
Ethanol, 99.97% QRec 
Ethyl acetoacetate Merck 
Petroleum ether QRec 
Piperidine Sigma-Aldrich 
Phosphorylchloride Merck 
Potassium carbonate anhydrous R & M Chemical 
Sodium carbonate Merck 
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3.2 Instruments 
 The instrumentation used for the qualitative characterization of synthesized 
starting materials and chalcone derivatives are listed below: 
 Thin Layer Chromatography (TLC) analyses were carried out using 
aluminium-backed silica gel 60 F254 plates. Visualization was done 
under UV light and by using iodine spotting. 
 CHN microanalyses were carried out on a Perkin Elmer 2400 LS 
Series CHNS/O analyzer at the School of Chemical Sciences, 
University Sains Malaysia (USM). 
 Fourier Transform Infrared (FT-IR) data were recorded using a Perkin 
Elmer 2000-FTIR spectrophotometer at the School of Chemical 
Sciences, USM. 
 1D and 2D Fourier Transform Nuclear Magnetic Resonance (FT-
NMR) spectroscopy performed using a Bruker AC 500 MHz at the 
School of Chemical Sciences, USM. 
 X-ray crystallographic analyses were done using either Bruker 
SMART Apex II or Apex II Duo CCD diffractometers at the School 
of Physical Sciences, USM. 
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3.3 Synthesis 
 The starting materials, aldehydes and ketones as well as the targeted 
chalcones were synthesized and purified at normal atmospheric pressure by 
conventional methods unless stated otherwise. 
3.3.1 Preparation of 2-alkyloxy-1-naphthaldehydes, 2-8  
 2-Alkyloxy-1-naphthaldehydes were synthesized according to the synthetic 
scheme below (Figure 3.1). 
OH
H
O
OR
H
O
2-81
CnH2n+1Br, K2CO3
DMF, 60-70 oC
 
n= 2, 4, 6, 8, 10, 12 and 14 
R = C2H5, C4H9, C6H13, C8H17, C10H21, C12H25, C14H29 
Figure 3.1: Synthetic scheme for the formation of 2-alkyloxy-1-naphthaldehyde, 2-8. 
2-Hydroxy-1-naphthaldehyde (2.00 g, 11.62 mmol) was mixed with 1.5 
equiv. of the corresponding bromoalkane in N,N-dimethylformamide (20.0 mL), 
which served as  a solvent. Three equiv. of potassium carbonate anhydrous was then 
added to the solution and the mixture was refluxed for 12 hours. The mixture was 
cooled to room temperature and poured into large amount of crushed ice with 
stirring. The resulting precipitate was filtered and washed with cold distilled water. 
The precipitate was air-dried and recrystallized from ethanol in cool condition. The 
scientific names and the respective R group for 2-8 are tabulated in Table 3.2. The 
condensed spectroscopy data for 2-8 can be found in Appendix I.  
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Table 3.2: Scientific name and respective R group of 2-8. 
Compound R group Scientific name 
2 C2H5 2-ethoxy-1-naphthaldehyde 
3 C4H9 2-butoxy-1-naphthaldehyde 
4 C6H13 2-hexoxy-1-naphthaldehyde 
5 C8H17 2-octoxy-1-naphthaldehyde 
6 C10H21 2-decoxy-1-naphthaldehyde 
7 C12H25 2-dodecoxy-1-naphthaldehyde 
8 C14H29 2-tetradecoxy-1-naphthaldehyde 
3.3.2 Preparation of 3-acetyl-4-hydroxycoumarin, 9 
3-Acetyl-4-hydroxycoumarin was synthesized according to the synthetic 
scheme below (Figure 3.2). 
O
OH
O
POCl3, AcOH
O
OH
O
CH3
O
9
115-120 oC
 
Figure 3.2: Synthetic scheme for the formation of 3-acetyl-4-hydroxycoumarin, 9. 
4-Hydroxycoumarin (3.00 g, 18.60 mmol) was added to acetic acid (16.00 
mL), which served as a reactant and solvent. Phosphorylchloride (5.60 mL) was then 
added to the solution and the mixture was refluxed for 12 hours (solution color 
changed from yellow to intense red). The mixture was cooled to room temperature 
and poured into large amount of crushed ice with stirring. The resulting precipitate 
was filtered and washed with cold distilled water. The precipitate was air-dried and 
recrystallized from ethanol.  
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3.3.3 Preparation of 3-acetylcoumarin, 10 
3-Acetylcoumarin was synthesized according to the synthetic scheme below 
(Figure 3.3). 
H
O
OH
+
H3C O CH3
O O
Piperidine
O O
CH3
O
10
EtOH, 65-75 oC
 
Figure 3.3: Synthetic scheme for the formation of 3-acetylcoumarin, 10. 
 Salicylaldehyde (2.70 mL, 25.00 mmol), ethyl acetoacetate (3.20 mL, 25.00 
mmol) and ethanol (50.00 mL) were all added into a 250 mL round-bottom flask. A 
catalytic amount of piperidine (0.50 mL) was added dropwise and the reaction 
mixture was refluxed at 65-75 oC for 4 hours. The mixture was cooled to room 
temperature. The resulting precipitate was filtered and washed with small portion of 
cold ethanol. The precipitate was air-dried and recrystallized from 
ethanol/chloroform mixture. 
3.3.4 Preparation of 3-acetyl-6,7-dimethyl-4-hydroxycoumarin, 11 
3-Acetyl-6,7-dimethyl-4-hydroxycoumarin was synthesized according to the 
synthetic scheme below (Figure 3.4). 
O
OH
O
POCl3,  AcOH
O
OH
O
CH3
O
11
115-120 oC
 
 
Figure 3.4: Synthetic scheme for the formation of 3-acetyl-6,7-dimethyl-4-
hydroxycoumarin, 11. 
 
